Related Experiment Video
Updated: Mar 7, 2026
Murine Prostate Micro-dissection and Surgical Castration
Published on: May 11, 2016
Methyl Jasmonate Ameliorates Testosterone Propionate-induced Prostatic Hyperplasia in Castrated Wistar Rats
Olubukola Oyebimpe Akanni1, Olusoji John Abiola2, Oluwatosin Adekunle Adaramoye1
1Drug Metabolism and Toxicology Research Laboratories, Department of Biochemistry, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Abstract:
Benign prostate hyperplasia (BPH) is a progressive disease that is related to age. Known therapeutic agents used in the treatment of BPH are associated with toxicity. Therefore, chemoprevention could be an effective approach. We investigated the ameliorative effects of methyl jasmonate (MeJA) in testosterone propionate (TP)-induced BPH in castrated rats. Castration was performed by removing both testes through the scrotum sack under ketamine anesthesia. Rats were assigned into seven groups of seven animals each: non-castrated control, castrated control, castrated rats that received TP, castrated rats that received TP and MeJA, castrated rats that received TP and finasteride, castrated rats that received MeJA, and castrated rats that received finasteride. Results indicate that BPH rats had significantly (p < 0.05) elevated prostate weight and relative weight of prostate relative to control. Also, BPH rats had significantly (p < 0.05) increased activities of prostatic acid and alkaline phosphatases, levels of zinc, and malondialdehyde. Further, levels of enzymic and non-enzymic antioxidative indices were significantly (p < 0.05) reduced in BPH. Histology of prostate revealed hyperplasia of transition lobe, increased expression of PSA, and Ki67 in BPH. Treatment with MeJA and finasteride attenuated the activities of the phosphatases and levels of antioxidants in BPH. Overall, MeJA ameliorates BPH via antioxidative mechanism. Copyright © 2017 John Wiley & Sons, Ltd.
Insights
Methyl jasmonate (MeJA) shows promise in preventing benign prostate hyperplasia (BPH) by reducing prostate weight and improving antioxidant levels in a rat model. This natural compound offers a potential chemopreventive strategy for BPH.
Area of Science:
- Urology
- Pharmacology
- Biochemistry
Background:
- Benign prostate hyperplasia (BPH) is an age-related condition with limited therapeutic options due to toxicity.
- Chemoprevention presents a viable alternative for managing BPH progression.
Purpose of the Study:
- To investigate the potential of methyl jasmonate (MeJA) as a chemopreventive agent for testosterone propionate (TP)-induced BPH in rats.
- To elucidate the underlying mechanisms of MeJA's effects on BPH.
Main Methods:
- Benign prostate hyperplasia was induced in castrated rats using testosterone propionate (TP).
- Animals were treated with MeJA or finasteride, and various biochemical and histological parameters were assessed.
- Prostate weight, phosphatase activities, antioxidant levels, PSA, and Ki67 expression were analyzed.
Main Results:
- TP-induced BPH in rats led to increased prostate weight, elevated phosphatase activities, and altered antioxidant status.
- MeJA treatment significantly attenuated these BPH-associated changes.
- Histological analysis showed reduced hyperplasia and normalized PSA and Ki67 expression with MeJA treatment.
Conclusions:
- Methyl jasmonate (MeJA) effectively ameliorates testosterone propionate-induced benign prostate hyperplasia in rats.
- The therapeutic effects of MeJA are attributed to its antioxidative properties.
- MeJA represents a potential natural chemopreventive agent for BPH.
